The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Feb. 10, 2026
Filed:
May. 13, 2022
Applicant:
Euclises Pharmaceuticals, Inc., Saint Louis, MO (US);
Inventors:
John J. Talley, Saint Louis, MO (US);
Bobby W. Sandage, Jr., Creve Coeur, MO (US);
Eduardo J. Martinez, Bryn Mawr, PA (US);
Assignee:
Euclises Pharmaceuticals, Inc., Saint Louis, MO (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/352 (2006.01); A61K 31/517 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01);
U.S. Cl.
CPC ...
A61K 31/352 (2013.01); A61K 31/517 (2013.01); A61K 39/3955 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01);
Abstract
The present disclosure provide a combination of a chromene compound having the structure of Formula (I), or pharmaceutically acceptable salts, and a second compound that can be selected from a PD-1 inhibitor, PD-L1 inhibitor, CTLA-4 inhibitor, OX-40 agonist, CD137 agonist, LAG-3 inhibitor, IDO inhibitor, bi-specific protein, EGFR inhibitor, HER2 inhibitor, and immune stimulating therapy and a method of using the combination for treating or preventing cancer.